Meeting abstracts from the 64th British Thyroid Association Annual Meeting
نویسندگان
چکیده
Graves’ orbitopathy (GO) is the main extrathyroidal manifestation of Graves’ disease. When fully expressed, it is characterized by inflammatory soft tissue changes, exophthalmos, ocular dysmotility causing diplopia, and, rarely, sight-threatening dysthyroid optic neuropathy (DON). The prevalence of GO among Graves’ patients seems lately declining, probably due to early diagnosis, early intervention on risk factors associated with its occurrence or progression (smoking, uncontrolled thyroid dysfunction), early correction of hyper and hypothyroidism. Only about 25–30% of newly diagnosed Graves’ hyperthyroids are affected with GO, which is usually mild and rarely progressive. Assessment of activity and severity of GO according to standardized criteria is fundamental to plan management. The European Thyroid Association and the European Group on Graves’ Orbitopathy (EUGOGO) have recently published the first guideline on management of GO. Mild GO usually requires only a watchful strategy, in addition to local measures (eye drops, ointments) and removal of risk factors. Intravenous glucocorticoids (ivGCs) are the first-line treatment for moderate-to-severe and active GO, as demonstrated by randomized clinical trials. When ivGCs fail or GO recurs after treatment withdrawal, options include a second course of ivGCs, oral GCs combined with orbital radiotherapy or cyclosporine, rituximab. Evidence that the any of the above treatment be effective in the context of a poor response to a first course of ivGCs is limited and should be investigated in larger studies. In addition to rituximab, ongoing investigations are exploring the role of other biologics targeting, e.g., the IGF-1 receptor or the IL-6 receptor, and results will probably available in 1–2 years. When GO has been treated medically and is inactive, rehabilitative surgery (orbital decompression, squint surgery, eyelid surgery) is often needed.
منابع مشابه
Abstracts of the ILAE British Branch Annual Scientific Meeting, University of Exeter, April 3–6, 2002
Abstracts of the ILAE British Branch Annual Scientific Meeting, University of Exeter, April 3–6, 2002s of the ILAE British Branch Annual Scientific Meeting, University of Exeter, April 3–6, 2002
متن کاملچکیده مقالات دهمین همایش پیاپی سالیانه انجمن علمی روانپزشکان ایران
10th Consecutive Annual Meeting of the Iranian Psychiatric Association Abstracts of the
متن کامل2011 ASCB Annual Meeting abstracts
The abstracts of the 2011 American Society for Cell Biology (ASCB) Annual Meeting are attached to this article as searchable PDF files. To view the files, click on the Abstracts link in the content box in the middle column of the HTML version of this article. The ASCB and the Editor-in-Chief of Molecular Biology of the Cell (MBoC) decided to present the Annual Meeting abstracts in this manner s...
متن کامل2013 ASCB Annual Meeting abstracts
The abstracts of the 2013 American Society for Cell Biology (ASCB) Annual Meeting are attached to this article as searchable PDF files. To view the files, click on the " Abstracts " link in the content box in the middle column of the HTML version of this article. The ASCB and the Editor-in-Chief of Molecular Biology of the Cell (MBoC) have decided to present the Annual Meeting abstracts in this...
متن کاملABSTRACTS Abstracts from the Thirty-second Annual Meeting of the Association for Chemoreception Sciences GIVAUDAN LECTURE - NORMAL AND CANCER STEM CELLS AND THE DEVELOPMENT OF MALIGNANCY 1 Normal and Cancer Stem Cells and the Development of Malignancy
Abstracts from the Thirty-second Annual Meeting of the Association for Chemoreception Sciencess from the Thirty-second Annual Meeting of the Association for Chemoreception Sciences GIVAUDAN LECTURE NORMAL AND CANCER STEM CELLS AND THE DEVELOPMENT OF MALIGNANCY 1 Normal and Cancer Stem Cells and the Development of Malignancy
متن کامل